-
Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy
-
Eui Bae Kim, Dae Sik Kim, Seh Jong Park, Yong Park, Kyoung Ho Rho, Seok Jin Kim
-
Cancer Res Treat. 2008;40(1):36-38. Published online March 31, 2008
-
DOI: https://doi.org/10.4143/crt.2008.40.1.36
-
-
Abstract
PDFPubReaderePub
Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin's lymphoma. However, its use has been implicated in HBV reactivation that's related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows: HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases.
-
Citations
Citations to this article as recorded by
- Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens
Rui Lu, Meng Zhang, Zi-Han Liu, Miao Hao, Yan Tian, Mei Li, Feng-Ping Wu, Wen-Jun Wang, Juan-Juan Shi, Xin Zhang, Xiao-Li Jia, Zi-Cheng Jiang, Xue-Mei Li, Guang-Hua Xu, Ya-Ping Li, Shuang-Suo Dang World Journal of Gastroenterology.2024; 30(44): 4725. CrossRef - Very late-onset hepatitis B reactivation following chemoimmunotherapy
Edward R. Scheffer Cliff, Joe Sasadeusz, Kumar Visvanathan, Andrew Grigg Leukemia & Lymphoma.2022; 63(4): 991. CrossRef - Development and validation of a nomogram for steroid-resistance prediction in immune thrombocytopenia patients
Jieni Yu, Zhiqiang Xu, Yuanyuan Zhuo, Huahua Wei, Yinhai Ye, Qinhong Xu, Youli Li, Lihong Yu, Weiying Feng, Pan Hong, Kejie Zhang Hematology.2021; 26(1): 956. CrossRef - Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency
Masako Hatano, Toshihide Mimura, Akira Shimada, Mitsuhiko Noda, Shigehiro Katayama Endocrinology, Diabetes & Metabolism.2019;[Epub] CrossRef - Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen
Nuria Dominguez, Maria Luisa Manzano, Raquel Muñoz, Ana Martin, Inmaculada Fernandez, Gregorio Castellano Leukemia & Lymphoma.2015; 56(4): 1160. CrossRef - Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?
Jesse Civan, Hie Won Hann Expert Opinion on Drug Safety.2015; 14(6): 865. CrossRef - Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy
Mauro Viganò, Giampaolo Mangia, Pietro Lampertico Expert Opinion on Biological Therapy.2014; 14(7): 1019. CrossRef - A Case of Reactivation of Hepatitis B and Fulminant Hepatitis which developed 3 months following Chemotherapy Including Rituximab in a Patient with Lymphoma
Tae Won Lim, Hee Taek Oh, Seung Un Song, Hae Won Lee, Ji Yeon Kim, Seon Ja Park Kosin Medical Journal.2014; 29(2): 161. CrossRef - Occult Hepatitis B Virus Infection: Transmission and Reactivation
Sang Hee Song, Seong Gyu Hwang The Korean Journal of Gastroenterology.2013; 62(3): 148. CrossRef - Reactivation of Hepatitis B Virus Following Systemic Chemotherapy for Malignant Lymphoma
Seung Jun Jang, Young Kul Jung, Hae Lim Baek, Hyun Hwa Yoon, Seung Kak Shin, Jun Shik Hong, Jin Ny Park, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Jae Hoon Lee, Ju Hyun Kim Korean Journal of Medicine.2013; 85(6): 598. CrossRef - Occult Hepatitis B: Clinical Viewpoint and Management
Mehdi Zobeiri Hepatitis Research and Treatment.2013; 2013: 1. CrossRef - Highly Sensitive Detection of Hepatitis B Virus Surface Antigen by Use of a Semiautomated Immune Complex Transfer Chemiluminescence Enzyme Immunoassay
Kazuhiko Takeda, Mari Maruki, Takahiro Yamagaito, Machiko Muramatsu, Yasuhiro Sakai, Hiroaki Tobimatsu, Hironori Kobayashi, Yoshiteru Mizuno, Yukio Hamaguchi Journal of Clinical Microbiology.2013; 51(7): 2238. CrossRef - Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy
Shigeru Kusumoto, Yasuhito Tanaka, Ryuzo Ueda, Masashi Mizokami Journal of Gastroenterology.2011; 46(1): 9. CrossRef - Fulminant Hepatic Failure with Hepatitis B Virus Reactivation after Rituximab Treatment in a Patient with Resolved Hepatitis B
Seong Min Chung, Joo Hyun Sohn, Tae Yeob Kim, Ki Deok Yoo, Yong Woo Ahn, Joong Ho Bae, Yong Cheol Jeon, Jung Hye Choi The Korean Journal of Gastroenterology.2010; 55(4): 266. CrossRef - Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B
Alessandro Allegra, Giuseppa Penna, Andrea Alonci, Angela Granata, Arianna D’Angelo, Caterina Musolino Medical Oncology.2010; 27(3): 912. CrossRef
-
14,285
View
-
91
Download
-
15
Crossref
|